427 related articles for article (PubMed ID: 15767355)
1. Serum levels of hepatocyte growth factor in patients with breast cancer.
Sheen-Chen SM; Liu YW; Eng HL; Chou FF
Cancer Epidemiol Biomarkers Prev; 2005 Mar; 14(3):715-7. PubMed ID: 15767355
[TBL] [Abstract][Full Text] [Related]
2. Circulating soluble Fas in patients with breast cancer.
Sheen-Chen SM; Chen HS; Eng HL; Chen WJ
World J Surg; 2003 Jan; 27(1):10-3. PubMed ID: 12557031
[TBL] [Abstract][Full Text] [Related]
3. Serum levels of soluble E-selectin in women with breast cancer.
Sheen-Chen SM; Eng HL; Huang CC; Chen WJ
Br J Surg; 2004 Dec; 91(12):1578-81. PubMed ID: 15386328
[TBL] [Abstract][Full Text] [Related]
4. Serum concentrations of hepatocyte growth factor in breast cancer patients.
Taniguchi T; Toi M; Inada K; Imazawa T; Yamamoto Y; Tominaga T
Clin Cancer Res; 1995 Sep; 1(9):1031-4. PubMed ID: 9816076
[TBL] [Abstract][Full Text] [Related]
5. Serum hepatocyte growth factor and interleukin-6 levels can distinguish patients with primary or metastatic liver tumors from those with benign liver lesions.
Coskun U; Bukan N; Sancak B; Günel N; Ozenirler S; Unal A; Yucel A
Neoplasma; 2004; 51(3):209-13. PubMed ID: 15254675
[TBL] [Abstract][Full Text] [Related]
6. Serum levels of circulating intercellular adhesion molecule-1 in patients with breast cancer.
Sheen-Chen SM; Eng HL; Sheen CW; Cheng YF; Chou FF; Chen WJ
Anticancer Res; 1997; 17(4A):2823-6. PubMed ID: 9252723
[TBL] [Abstract][Full Text] [Related]
7. Association of immunoreactive hepatocyte growth factor with poor survival in resectable non-small cell lung cancer.
Siegfried JM; Weissfeld LA; Singh-Kaw P; Weyant RJ; Testa JR; Landreneau RJ
Cancer Res; 1997 Feb; 57(3):433-9. PubMed ID: 9012470
[TBL] [Abstract][Full Text] [Related]
8. Significance of circulating hepatocyte growth factor level as a prognostic indicator in primary breast cancer.
Toi M; Taniguchi T; Ueno T; Asano M; Funata N; Sekiguchi K; Iwanari H; Tominaga T
Clin Cancer Res; 1998 Mar; 4(3):659-64. PubMed ID: 9533534
[TBL] [Abstract][Full Text] [Related]
9. Clinical value of serum hepatocyte growth factor, B-cell lymphoma-2 and nitric oxide in primary breast cancer patients.
Ahmed HH; Metwally FM; Mahdy ES; Shosha WG; Ramadan SS
Eur Rev Med Pharmacol Sci; 2012 Jul; 16(7):958-65. PubMed ID: 22953646
[TBL] [Abstract][Full Text] [Related]
10. Tumor HGF lacks prognostic significance in Mexican breast cancer patients.
Pruefer FG; Unger-Saldaña K; Mohamier L; Ramírez M; Suárez J; Ramirez MT; Maldonado V; Meléndez-Zajgla J
J Exp Clin Cancer Res; 2006 Sep; 25(3):357-64. PubMed ID: 17167976
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of predictive and prognostic significance of serum TGF-beta1 levels in breast cancer according to HER-2 codon 655 polymorphism.
Papadopoulou E; Anagnostopoulos K; Tripsianis G; Tentes I; Kakolyris S; Galazios G; Sivridis E; Simopoulos K; Kortsaris A
Neoplasma; 2008; 55(3):229-38. PubMed ID: 18348656
[TBL] [Abstract][Full Text] [Related]
12. Circulating level of hepatocyte growth factor as a useful tumor marker in patients with early-stage gastric carcinoma.
Tanaka K; Miki C; Wakuda R; Kobayashi M; Tonouchi H; Kusunoki M
Scand J Gastroenterol; 2004 Aug; 39(8):754-60. PubMed ID: 15513361
[TBL] [Abstract][Full Text] [Related]
13. Hepatocyte growth factor profile with breast cancer.
El-Attar HA; Sheta MI
Indian J Pathol Microbiol; 2011; 54(3):509-13. PubMed ID: 21934211
[TBL] [Abstract][Full Text] [Related]
14. Significance of serum hepatocyte growth factor levels in patients with hepatocellular carcinoma undergoing hepatic resection.
Chau GY; Lui WY; Chi CW; Chau YP; Li AF; Kao HL; Wu CW
Eur J Surg Oncol; 2008 Mar; 34(3):333-8. PubMed ID: 17218078
[TBL] [Abstract][Full Text] [Related]
15. Predictive value of plasma hepatocyte growth factor/scatter factor levels in patients with clinically localized prostate cancer.
Gupta A; Karakiewicz PI; Roehrborn CG; Lotan Y; Zlotta AR; Shariat SF
Clin Cancer Res; 2008 Nov; 14(22):7385-90. PubMed ID: 19010854
[TBL] [Abstract][Full Text] [Related]
16. [Relationship and expression of hepatocyte growth factor and vascular endothelial growth factor in serum preoperative and postoperative patients with laryngeal squamous cell cancer].
Wang Y; Zhao H; Chen J; Liu L; Zhang P; Che J; Wang G
Lin Chuang Er Bi Yan Hou Tou Jing Wai Ke Za Zhi; 2010 Dec; 24(24):1112-5. PubMed ID: 21395178
[TBL] [Abstract][Full Text] [Related]
17. Immunoreactive hepatocyte growth factor is a strong and independent predictor of recurrence and survival in human breast cancer.
Yamashita J; Ogawa M; Yamashita S; Nomura K; Kuramoto M; Saishoji T; Shin S
Cancer Res; 1994 Apr; 54(7):1630-3. PubMed ID: 8137271
[TBL] [Abstract][Full Text] [Related]
18. Serum active hepatocyte growth factor (AHGF) in benign prostatic disease and prostate cancer.
Yasuda K; Nagakawa O; Akashi T; Fujiuchi Y; Koizumi K; Komiya A; Saiki I; Fuse H
Prostate; 2009 Mar; 69(4):346-51. PubMed ID: 19021204
[TBL] [Abstract][Full Text] [Related]
19. [mRNA expression of basic fibroblast growth factor and hepatocyte growth factor in gastric carcinoma and significance thereof].
Ru GQ; Zhao ZS; Tang QL; Xu WJ
Zhonghua Yi Xue Za Zhi; 2008 Jul; 88(29):2030-5. PubMed ID: 19080429
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of soluble adhesion molecules CD44 (CD44st, CD44v5, CD44v6), ICAM-1, and VCAM-1 as tumor markers in head and neck cancer.
Kawano T; Yanoma S; Nakamura Y; Shiono O; Kokatu T; Kubota A; Furukawa M; Tsukuda M
Am J Otolaryngol; 2005; 26(5):308-13. PubMed ID: 16137528
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
